Proteostasis Therapeutics Inc. (PTI) and Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) Contrasting side by side

Proteostasis Therapeutics Inc. (NASDAQ:PTI) and Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteostasis Therapeutics Inc. 2.84M 23.18 61.83M -1.76 0.00
Aerpio Pharmaceuticals Inc. 20.16M 1.97 10.40M -0.44 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Proteostasis Therapeutics Inc. and Aerpio Pharmaceuticals Inc.


Table 2 has Proteostasis Therapeutics Inc. and Aerpio Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Proteostasis Therapeutics Inc. -2,177.11% -104.1% -76.7%
Aerpio Pharmaceuticals Inc. -51.59% -22.7% -18.5%


The Current Ratio of Proteostasis Therapeutics Inc. is 4.2 while its Quick Ratio stands at 4.2. The Current Ratio of rival Aerpio Pharmaceuticals Inc. is 19.2 and its Quick Ratio is has 19.2. Aerpio Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Proteostasis Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 82.9% of Proteostasis Therapeutics Inc. shares and 26.6% of Aerpio Pharmaceuticals Inc. shares. Insiders held roughly 0.9% of Proteostasis Therapeutics Inc.’s shares. Comparatively, Aerpio Pharmaceuticals Inc. has 0.8% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteostasis Therapeutics Inc. 9.31% 47.68% -18.17% 75.59% 43.41% 37.65%
Aerpio Pharmaceuticals Inc. -2.05% -17.82% 48.96% -17.82% -41.63% 68.24%

For the past year Proteostasis Therapeutics Inc.’s stock price has smaller growth than Aerpio Pharmaceuticals Inc.


Aerpio Pharmaceuticals Inc. beats Proteostasis Therapeutics Inc. on 9 of the 10 factors.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.